Armata Pharmaceuticals (ARMP) details Q3 2025 results in November 12 press release

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. filed a current report to note that it has announced its financial results for the three and nine months ended September 30, 2025. The company released these results in a press release dated November 12, 2025, which is attached as Exhibit 99.1.

The company states that the information in this results announcement and the related exhibit is being furnished, not filed, under securities laws, and will not be incorporated by reference into any registration statement or other document under the Securities Act of 1933.

false000092111400009211142025-11-122025-11-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 12, 2025

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

​

Washington	001-37544	91-1549568
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

​

​

​ ​	​ ​
5005 McConnell Avenue Los Angeles, California	​ 90066
(Address of principal executive offices)	(Zip Code)

​

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock	​	ARMP	​	NYSE American

​

​

​

​

​

​

Item 2.02Results of Operations and Financial Condition.

​

On November 12, 2025, the Company announced its financial results for the three and nine months ended September 30, 2025, in the press release furnished hereto as Exhibit 99.1.

​

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

​

​

​

Item 9.01Financial Statements and Exhibits.

​

(d)Exhibits.

​

​	​	​
Exhibit No.		Description
99.1	​	Press Release, dated November 12, 2025.
104	​	Cover Page Interactive Data File (embedded within Inline XBRL document).

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
Date: November 12, 2025	Armata Pharmaceuticals, Inc.
​	​
​	By:	/s/ David House
​	Name:	David House
​	Title:	Senior Vice President, Finance and Principal Financial Officer

​

​

​

​

​

FAQ

What did Armata Pharmaceuticals (ARMP) disclose in this 8-K filing?

Armata Pharmaceuticals disclosed that it announced its financial results for the three and nine months ended September 30, 2025, in a press release dated November 12, 2025, furnished as Exhibit 99.1.

Where can investors find the Q3 2025 results for Armata Pharmaceuticals (ARMP)?

Investors can find the financial results for the three and nine months ended September 30, 2025, in the press release attached to the filing as Exhibit 99.1.

Are Armata Pharmaceuticals’ Q3 2025 results considered filed with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Will the Armata Pharmaceuticals (ARMP) press release be incorporated into registration statements?

The company states that the information in Item 2.02 and Exhibit 99.1 will not be incorporated by reference into any registration statement or other document under the Securities Act of 1933.

What exhibits are included in this Armata Pharmaceuticals (ARMP) 8-K?

The filing includes Exhibit 99.1, a press release dated November 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Armata Pharmaceuticals (ARMP) 8-K report?

The report was signed on behalf of Armata Pharmaceuticals, Inc. by David House, Senior Vice President, Finance and Principal Financial Officer, dated November 12, 2025.